.Attribute Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin caused improved progression-free and also general survival, leading to FDA approval and also a new therapy possibility for patients.